Item 7.01 Regulation FD Disclosure.

Markus Renschler, MD, President and Chief Executive Officer of Cyteir Therapeutics, Inc. (the "Company"), will virtually present the information in the Company's presentation attached hereto as Exhibit 99.1 (the "Presentation") at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. Spokespersons of the Company also plan to present the information in the Presentation at various meetings beginning on January 11, 2022, including investor and analyst meetings.

The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements. The Presentation contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Presentation regarding these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          Investor Presentation, dated January 11, 2022

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses